The clinical response to treatment with the IL-1 receptor antagonist anakinra mirrors the increased presence of IL-1β in FACAS tissue similar to other urticarial autoinflammatory diseases such as CAPS. Here, IL1B is linked to cryopyrin-associated periodic syndrome.